MSOT as Non-invasive Biomarker for Diagnosis and Monitoring of Neuromuscular Diseases

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeUp to 18
SponsorChildren's Hospital of Eastern Ontario

About this trial

The goal of this study is to learn if Multispectral Optoacoustic Tomographs (MSOT) works to diagnose and follow the course of neuromuscular diseases (NMDs) in children. MSOT scans will be obtained from muscle region to measure hemo/myoglobin, collagen and lipid content/signal and oxygenation in patients with neuromuscular diseases. No additional research activities -other than MSOT - will be done during this study. Existing clinical, laboratory and imaging data from standard-of-care procedures will be correlated with the MSOT data. The expected total duration of the study is approximately 36 months. Repeated measurements will be done to evaluate disease progression and the value of MSOT in NMD.

Eligibility criteria

Qualifiers

Children (from birth (infants that are born term) to 18 years of age) participants or consent through authorized guardian

Confirmed or suspected diagnosis of a neuromuscular disease (through molecular genetics, biopsy, clinical examination)

Disqualifiers

Diagnosis is not consistent with a confirmed or suspected neuromuscular disease

Patients with active skin lesions (e.g. infections, trauma) or confirmed genetic disorders (e.g. epidermolysis bullosa) that predisposes to skin lesion

Medically unstable patients

Tattoo on skin overlying the area to be examined

Trial design

Treatments tested in this trial

  • Multispectral Optoacoustic Tomography (MSOT)

Treatment groups

240 Participants
are divided into 1 treatment group